Download PDF

This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.

Valid: April 15th, 2010 - April 15th, 2011

Target Audience
This activity was developed for pharmacists and other healthcare professionals practicing in a managed care environment.

Learning Objectives
At the completion of this activity participants should be able to:

  • Provide payers with a practical understanding of the key clinical, business, and regulatory factors, guidelines, and research advances involving NHL treatment that providers are using as the basis for their treatment decisions
  • Offer payers a multistakeholder commentary on this information, to identify the impact of these changes to treatment on different stakeholders
  • Illuminate the different perspectives and incentives of the various stakeholders involved in NHL treatment decisions: patients, providers, payers, purchasers, distributors, regulatory agencies, and manufacturers
  • Align incentives with providers and transform payer drug management policies into patient-centered, value-based models


Pharmacists Designation
Medical Learning Institute (MLI) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Completion of this activity provides for 1.0 contact hour (0.1 CEU) of continuing education credit. The universal activity number for this activity is 0468-9999-10-014-H01-P.

Disclosure Statement
Before the activity, all faculty will disclose the existence of any financial interest and/or relationship(s) they might have with the manufacturer(s) of any commercial product(s) to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speaker's bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions.

The associates of Medical Learning Institute, Inc., and Center of Excellence Media, LLC, have no financial relationships to disclose.

Caroline Helwick has no financial relationships to disclose.


Faculty Disclosures
Dwight D. Kloth, PharmD, FCCP, BCOP, is on the Advisory Board of Amgen, Eisai, and Ortho-Biotech, and on the Speaker's Bureau of Amgen. He discusses bendamustine plus rituximab combination.

Gary C. Yee, PharmD, FCCP, BCAP, is on the Advisory Board of Amgen and Eisai. He discusses bendamustine, bortezomib, ofatumumab, and temsirolimus.

*Content will include non-FDA-approved uses.


The information provided in this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.

Related Items
Considerations in Lymphoma Ask The Experts: Mantle Cell Lymphoma
Mitchell R. Smith, MD, PhD, Barbara B. Rogers, CRNP, MN, AOCN, ANP-BC, Dwight D. Kloth, PharmD, FCCP, BCOP
Supplements published on June 11, 2012
The Evolving Role of Outcomes and End Points in Evaluating Therapy for Hematologic Malignancies: Value-Driven Benefit Design and Utilization Management Strategies
Gary C. Yee, PharmD, FCCP, BCOP, James T. Kenney Jr, RPh, MBA, Michael Mauro, MD
Supplements published on July 15, 2011
Cutaneous and Peripheral T-Cell Lymphomas: The Latest in Treatment Advances and Management Strategies
Gary C. Yee, PharmD, FCCP, BCOP, Robin Gemmill, RN, MSN, CNS, CWOCN
Supplements published on September 10, 2009
Current and Future Perspectives on the Treatment of Cutaneous T-cell Lymphoma and Peripheral T-cell Lymphoma
Sue McCann, RN, BSN, DCN, Gary C. Yee, PharmD, FCCP, BCOP
Supplements published on October 31, 2008
Last modified: March 21, 2014